First — I'm glad your GI doctor identified this and you're getting appropriate management. This is an important topic.
Let me clarify a critical distinction:
GLP-1 RAs delay gastric emptying by design. That is one of their primary mechanisms of action — it's how they reduce appetite and improve postprandial glucose control. A degree of slowed emptying is expected and therapeutic.
Gastroparesis is when that slowing becomes pathological — causing symptoms like persistent nausea, vomiting of undigested food, early satiety beyond what's functional, and demonstrable delayed emptying on a standardized gastric emptying study.
The key question is whether this represents:
- Drug-induced gastroparesis — the GLP-1 RA has slowed emptying beyond the therapeutic range. This typically reverses after discontinuation (within 2-5 half-lives, so several weeks for semaglutide).
- Unmasked underlying gastroparesis — you may have had subclinical gastroparesis (common in patients with metabolic syndrome, diabetes, or prior abdominal surgeries) that became symptomatic when the drug slowed things further. This may or may not fully reverse.
In most cases I've seen, gastric emptying normalizes within 4-8 weeks of discontinuation. The prognosis is generally good.
Last edited: Aug 30, 2025 at 7:17 PM